Stellabody^®

Improving the efficacy of cancer, inflammation
and infectious disease treatments

Stellabody^® hexamer technology is an adaptable and multifunctional transformative discovery that dramatically improves the potency of antibodies and antibody-like biologics leading to the creation of function-enhanced therapeutics for the treatment of cancer, inflammation and infection.

Stellabody^® is up to 100 times
more effective at cell killing than
standard antibody therapeutics.

The technology is a change to the Fc of antibodies which exploits their natural behaviour, resulting in the formation of hexameric clusters of the antibodies after they bind to their target. These Stellabody^® hexamers are the ideal format to potently harness immune effector systems, such as complement, or to amplify receptor signals, such as apoptosis in cells.

The Need

The development of antibody and biological therapies has two key challenges:

Monoclonal antibodies and their antibody-like cousins, such as Fc fusion proteins, are potential biological medicines that will readily target cancers, inflammatory cells or microbes but often have insufficient potency and lack efficacy.
Technology is needed to develop new and powerful next-generation therapeutic antibodies and to overcome limitations of existing antibody therapeutics to broaden their application.

This is where Stellabody^® technology comes in.

The Need

The development of antibody and biological therapies has two key challenges:

Monoclonal antibodies and their antibody-like cousins, such as Fc fusion proteins, are potential biological medicines that will readily target cancers, inflammatory cells or microbes but often have insufficient potency and lack efficacy.
Technology is needed to develop new and powerful next-generation therapeutic antibodies and to overcome limitations of existing antibody therapeutics to broaden their application.

This is where Stellabody^® technology comes in.

The Technology

Stellabody^® hexamer technology was discovered in the Hogarth Immune Therapies Group at Burnet Institute, one of the most globally accomplished laboratories in this field.

Professor Hogarth has researched antibodies, their effector functions and roles in immunity and inflammation for over 30 years.

Stellabody^® hexamer technology confers greater potency for cell killing and signal amplification in antibodies and antibody-like biologics.

How does it work?

Stellabody^® hexamer technology works by exploiting the normal biology of antibodies and drives them into formation clusters of six antibodies (hexameric clusters) once they have bound to their target e.g. cancer cell.

These 'on-target' hexamers are the ideal format to initiate effector responses or amplify the signals of cell surface receptors, thereby conferring potent effector actions on the antibody or antibody-like biological.

What is serum complement?

Human serum contains a collection of proteins called the complement system which is one of the most powerful destructive systems used by antibodies.

The Stellabody^® hexamers create the optimal platform for the activation of this complement 'cascade' system once the Stellabody is bound to its target. Stellabody can completely transform ineffective antibodies to potent complement-dependent killers.

What is signal amplification?

Cell surface receptors normally deliver signals cells. Antibodies or antibody-like molecules can poorly cluster these receptors and deliver weak signals.

Stellabody^® technology clusters these receptors into hexamers which in turn initiates more powerful signals. One example is the amplification of apoptosis signals which result in the death of the targeted cell.

Read Frontiers in Immunology published article:
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV-2

The Use Cases

Stellabody^® is a powerful and versatile technology adaptable to multiple antibody formats against a broad range of targets, with applications in a wide range of disease settings across cancer, inflammation and infectious disease.

Click on each of the below for examples of Stellabody^® hexamer application:

The Opportunity

Stellabody^® is a patented technology owned by Burnet Institute.

We are seeking partnership with antibody development companies and funders to help progress this versatile and exciting technology.

Hexamerisation technology is exploitable and valuable. A recent licence of hexamer technology for a CD38 mAb exceeded US$200 million plus an additional royalty stream.
The current CD38 market exceeds US$10 billion per annum.

Join us in transforming the potency and killing power of antibody and antibody-like therapeutics with Stellabody^®, and make a valuable and powerful impact in the treatment of cancer, inflammation and infection.

The Opportunity

Stellabody^® is a patented technology owned by Burnet Institute.

We are seeking partnership with antibody development companies and funders to help progress this versatile and exciting technology.

Join us in transforming the potency and killing power of antibody and antibody-like therapeutics with Stellabody^®, and make a valuable and powerful impact in the treatment of cancer, inflammation and infection.